Alpha 1-antitrypsin deficiency other diagnostic studies

Jump to navigation Jump to search

Alpha 1-antitrypsin deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alpha 1-antitrypsin deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alpha 1-antitrypsin deficiency other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alpha 1-antitrypsin deficiency other diagnostic studies

CDC on Alpha 1-antitrypsin deficiency other diagnostic studies

Alpha 1-antitrypsin deficiency other diagnostic studies in the news

Blogs on Alpha 1-antitrypsin deficiency other diagnostic studies

Directions to Hospitals Treating Alpha 1-antitrypsin deficiency

Risk calculators and risk factors for Alpha 1-antitrypsin deficiency other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

Patients with low or borderline serum levels are tested with phenotyping (serum levels < 100 mg/dL) by isoelectric focusing (IEF) is the most commonly used method to definitively detect the alpha1-antitrypsin phenotype that indicates a risk for AATD. Genotyping uses DNA extracted from circulating mononuclear blood cells that utilizes DNA amplification techniques with melt-curve analysis.

Other Diagnostic Studies

Phenotyping

Patients with low or borderline serum levels are tested with phenotyping (serum levels < 100 mg/dL) by isoelectric focusing (IEF) is the most commonly used method to definitively detect the alpha1-antitrypsin phenotype that indicates a risk for AATD.[1][2]

Phenotyping is required to confirm AATD. Do not initiate alpha1-antitrypsin replacement therapy without testing.

Genotyping

Genotyping uses DNA extracted from circulating mononuclear blood cells that utilizes DNA amplification techniques with melt-curve analysis.

References

  1. Ljujic M, Topic A, Divac A, Nikolic A, Petrovic-Stanojevic N, Surlan M, Mitic-Milikic M, Radojkovic D (2008). "Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants". Transl Res. 151 (5): 255–9. doi:10.1016/j.trsl.2008.02.002. PMID 18433707.
  2. Al-Jameil N, Hassan AA, Buhairan A, Hassanato R, Isac SR, Al-Otaiby M, Al-Maarik B, Al-Ajeyan I (2017). "Genotyping diagnosis of alpha-1 antitrypsin deficiency in Saudi adults with liver cirrhosis". Medicine (Baltimore). 96 (6): e6071. doi:10.1097/MD.0000000000006071. PMC 5313019. PMID 28178162.


Template:WikiDoc Sources